Literature DB >> 8321842

Pharmacokinetic analysis of an oral sustained-release diltiazem preparation using multifraction absorption models.

K Murata1, K Noda.   

Abstract

Application of multifraction absorption models to pharmacokinetic analysis of an oral sustained-release diltiazem preparation (HER-SR) was investigated. The plasma diltiazem concentrations after oral administration of the HER-SR preparation were analyzed using both the two-fraction absorption model and the two-step discontinuous absorption model. The two-fraction absorption model was suitable for the pharmacokinetic analysis of the HER-SR preparation, whereas the two-step discontinuous absorption model is often unsuitable for the analysis of sustained-release preparations which disintegrate into fractions with different release characteristics in the gastrointestinal tract. The two-step discontinuous absorption model is usually not applicable to plasma concentration data when the first peak is sharp. MFA-MULTI(V) was shown to be useful for the prediction of the bioavailability in each fraction of HER-SR. It was further demonstrated that a two-fraction absorption model is useful for the comparison of in vitro and in vivo release profiles or evaluating the influence of food on the absorption behavior of HER-SR. In addition, the application of a two-fraction absorption model to population pharmacokinetics of HER-SR was investigated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321842     DOI: 10.1023/a:1018976203610

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

1.  KINETIC ANALYSIS OF BLOOD LEVELS AND URINARY EXCRETION IN THE ABSORPTIVE PHASE AFTER SINGLE DOSES OF DRUG.

Authors:  J G WAGNER; E NELSON
Journal:  J Pharm Sci       Date:  1964-11       Impact factor: 3.534

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Pharmacokinetic analysis of single- or multiple-dose plasma drug concentration data with a microcomputer using multi-fraction absorption models.

Authors:  K Murata; K Tagawa; K Noda; M Samejima
Journal:  J Pharm Sci       Date:  1989-02       Impact factor: 3.534

4.  A new version of MULTI (ELS) for extended nonlinear least squares.

Authors:  K Yamaoka; H Tanaka
Journal:  J Pharmacobiodyn       Date:  1987-01

5.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

6.  Pharmacokinetic analysis of concentration data of drugs with irregular absorption profiles using multi-fraction absorption models.

Authors:  K Murata; K Noda; K Kohno; M Samejima
Journal:  J Pharm Sci       Date:  1987-02       Impact factor: 3.534

7.  Discontinuous absorption processes in pharmacokinetic models.

Authors:  R Süverkrüp
Journal:  J Pharm Sci       Date:  1979-11       Impact factor: 3.534

8.  A nonlinear multiple regression program, MULTI2 (BAYES), based on Bayesian algorithm for microcomputers.

Authors:  K Yamaoka; T Nakagawa; H Tanaka; M Yasuhara; K Okumura; R Hori
Journal:  J Pharmacobiodyn       Date:  1985-04

9.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

10.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
View more
  2 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Pharmacokinetics of diltiazem and its metabolites in dogs after oral administration of a multiparticulate sustained-release preparation.

Authors:  K Murata; H Yamahara; K Noda
Journal:  Pharm Res       Date:  1993-08       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.